Home > Neurology > AAN 2019 > Headache and Migraine > Lasmiditan: rapid onset of efficacy in acute migraine

Lasmiditan: rapid onset of efficacy in acute migraine

Conference
AAN 2019
Trial
Phase 3, SPARTAN, SAMURAI
Lasmiditan is a novel selective 5-HT1F receptor agonist that lacks vasoconstrictive activity. Patients treated for a single migraine attack reported earlier onset of efficacy with oral lasmiditan compared to placebo. Some of the efficacy measures improved as early as 30 minutes after active treatment [1]. This was concluded from an analysis of two placebo-controlled phase 3 trials: SPARTAN and SAMURAI. In both studies, lasmiditan met co-primary and secondary efficacy endpoints at 2 hours following initial dose. The goal of the integrated analysis was to evaluate onset of the following efficacy measures: pain freedom, total migraine freedom, most bothersome symptom freedom, pain relief, freedom from associated individual symptoms (photophobia, phonophobia, or nausea), and patient-reported ‘no disability’ due to migraine. From 60 minutes onwards, rates of pain freedom and total migraine freedom were significantly higher in lasmiditan 100 and 200 mg groups co...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on